Proactive Investors - Run By Investors For Investors

Genprex making strides to take cancer-fighting drug Oncoprex to FDA approval

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive Investors the bio-pharmaceutical company is making great strides toward developing the company's non-small-cell, lung cancer-fighting, gene-therapy drug Oncoprex.

Varner says Oncoprox is in Phase 2 of clinical trials, and next steps are to meet with the FDA about best pathways forward to an approval.

The company recently went public, raising $6.4mln. Varner says the biopharma will use the funds to continue clinical trials and expand and/or accelerate development programs into additional drug combinations.

 
Meet ICOx Innovations at our event, New York , 30 January 2019. Register here »
View full GNPX profile View Profile

Genprex, Inc. Timeline

Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use